Analysts See $-0.33 EPS for Exact Sciences Corporation (EXAS)

July 27, 2018 - By Vernon Prom

Exact Sciences Corporation (NASDAQ:EXAS) LogoInvestors sentiment increased to 1.15 in Q1 2018. Its up 0.27, from 0.88 in 2017Q4. It improved, as 43 investors sold Exact Sciences Corporation shares while 80 reduced holdings. 54 funds opened positions while 88 raised stakes. 101.92 million shares or 10.20% more from 92.48 million shares in 2017Q4 were reported.
Janney Montgomery Scott Ltd Llc holds 6,797 shares. Nuveen Asset Mgmt Ltd Llc invested 0.01% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS). 84,932 were accumulated by Employees Retirement Systems Of Ohio. Perigon Wealth Mngmt Limited Liability Corp, California-based fund reported 314 shares. Virtu Limited Liability Co holds 0.12% of its portfolio in Exact Sciences Corporation (NASDAQ:EXAS) for 56,757 shares. 151,158 were reported by Axa. Strs Ohio stated it has 45,300 shares. Raymond James And holds 90,363 shares or 0.01% of its portfolio. Blair William And Il has 664,538 shares. 2,410 are held by Crow Point Ptnrs Limited Com. Redmond Asset Ltd Limited Liability Company holds 10,745 shares. New York-based Metropolitan Life Ins has invested 0% in Exact Sciences Corporation (NASDAQ:EXAS). Sit Inc holds 0.03% or 26,800 shares. The New York-based Oppenheimer & has invested 0.01% in Exact Sciences Corporation (NASDAQ:EXAS). Savings Bank Of Montreal Can, Ontario – Canada-based fund reported 4,386 shares.

Since February 9, 2018, it had 0 buys, and 18 insider sales for $12.83 million activity. ARORA MANEESH also sold $522,959 worth of Exact Sciences Corporation (NASDAQ:EXAS) shares. On Monday, February 26 LIDGARD GRAHAM PETER sold $1.50M worth of Exact Sciences Corporation (NASDAQ:EXAS) or 35,025 shares. $126,252 worth of Exact Sciences Corporation (NASDAQ:EXAS) was sold by Elliott Jeffrey Thomas. 11,459 shares were sold by Conroy Kevin T, worth $598,091. On Tuesday, April 10 Carey Thomas D. sold $335,630 worth of Exact Sciences Corporation (NASDAQ:EXAS) or 8,448 shares. 7,402 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $381,447 were sold by WYZGA MICHAEL S.

Analysts expect Exact Sciences Corporation (NASDAQ:EXAS) to report $-0.33 EPS on August, 1 after the close.They anticipate $0.06 EPS change or 22.22 % from last quarter’s $-0.27 EPS. After having $-0.33 EPS previously, Exact Sciences Corporation’s analysts see 0.00 % EPS growth. The stock decreased 1.07% or $0.67 during the last trading session, reaching $61.91. About 1.30 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 56.13% since July 27, 2017 and is uptrending. It has outperformed by 43.56% the S&P500.

Exact Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 11 analysts covering Exact Sciences (NASDAQ:EXAS), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Exact Sciences has $8500 highest and $50.0 lowest target. $67.75’s average target is 9.43% above currents $61.91 stock price. Exact Sciences had 20 analyst reports since January 29, 2018 according to SRatingsIntel. The firm has “Buy” rating by Leerink Swann given on Wednesday, March 28. Benchmark downgraded the shares of EXAS in report on Friday, February 23 to “Hold” rating. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Canaccord Genuity on Friday, April 27. Canaccord Genuity maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Friday, February 23. Canaccord Genuity has “Buy” rating and $55.0 target. The company was maintained on Tuesday, June 5 by Robert W. Baird. Cowen & Co maintained the shares of EXAS in report on Monday, June 18 with “Buy” rating. The stock of Exact Sciences Corporation (NASDAQ:EXAS) has “Buy” rating given on Monday, July 23 by Bank of America. The company was maintained on Friday, June 15 by Canaccord Genuity. The rating was maintained by Leerink Swann on Thursday, July 19 with “Outperform”. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by William Blair on Thursday, March 29.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $7.57 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

More news for Exact Sciences Corporation (NASDAQ:EXAS) were recently published by:, which released: “Buy the Dip on Exact Sciences Stock” on July 03, 2018.‘s article titled: “Why Exact Sciences Shares Are Rallying 13.8% in 2018” and published on July 07, 2018 is yet another important article.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.